CN103550204A - Application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments - Google Patents
Application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments Download PDFInfo
- Publication number
- CN103550204A CN103550204A CN201310496280.5A CN201310496280A CN103550204A CN 103550204 A CN103550204 A CN 103550204A CN 201310496280 A CN201310496280 A CN 201310496280A CN 103550204 A CN103550204 A CN 103550204A
- Authority
- CN
- China
- Prior art keywords
- neonectrolide
- helicobacter pylori
- preparation
- medicaments
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments. The Neonectrolide A can be used for treating acute and chronic gastritis, gastric ulcer, duodenal ulcer and other diseases and be applied to preparation of medicaments for treating the acute and chronic gastritis, the gastric ulcer and the duodenal ulcer. As the framework type belongs to a band new framework type and the Neonectrolide A further has strong activity of inhibiting helicobacter pylori, the Neonectrolide A has prominent substantive characteristics and also has significant progress in prevention and treatment of helicobacter pylori infection.
Description
Technical field
The present invention relates to the new purposes of compound N eonectrolide A, relate in particular to the application of Neonectrolide A in preparing Anti-helicobacter pylori drugs.
Background technology
Helicobacter pylori (Helicobacter pylori, Hp) is a kind of Gram-negative spiral bacteria.Studies show that, helicobacter pylori is the main pathogenesis of acute and chronic gastritis and Stomach duodenum ulcer, and may be relevant with the morbidity of gastric cancer stomach function regulating mucosa-associated lymphoid tissue (MALT) malignant lymphoma.Recently, World Health Organization (WHO) is classified as I class carcinogen by Hp, and it plays a leading role in gastric cancer development.The scheme that at present popular treatment Hp infects is to take the triple therapy that proton pump inhibitor (PPI) adds two kinds of antibiotic (clarithromycin, amoxicillin, tetracycline, metronidazole etc. select two kinds) simultaneously.The main factor that affects triple therapy is considered to the drug resistance of Hp to antibacterial; Another serious problems are that proton pump inhibitor can bring out dyspepsia, and a large amount of antibacterial cause the serious destruction of flora in digestive tract.Therefore, find the active kind new medicine thing of efficient, safe anti-Hp and become an important and urgent task.
The compound N eonectrolide A the present invention relates to is one and within 2012, delivers (Jinwei Ren, et al., Neonectrolide A, a New Oxaphenalenone Spiroketal from the Fungus Neonectria sp.Organic Letters, 2012, 14(24) 6226 – 6229.) noval chemical compound, this compound has brand-new framework types, current purposes only relates to and suppresses part tumor cell proliferation (Jinwei Ren, et al., Neonectrolide A, a New Oxaphenalenone Spiroketal from the Fungus Neonectria sp.Organic Letters, 2012, 14(24) 6226 – 6229.), it is open first that the purposes of the Neonectrolide A the present invention relates in preparing Anti-helicobacter pylori drugs belongs to.
Summary of the invention
The object of the invention is to, according to not finding that it has the present situation of the report of anti-helicobactor pylori activity in existing Neonectrolide A research, provides the application of Neonectrolide A in preparing Anti-helicobacter pylori drugs.
Described compound N eonectrolide A, structure is as shown in formula I:
The experiment in vitro of Neonectrolide A shows, Neonectrolide A has very strong anti Helicobacter pylori activity, and paper disk method shows that its antibacterial circle diameter is 17mm (ATCC43504).With agar dilution, show that it can suppress the growth of 5 random clinical strains (Hp001, Hp003, Hp004, Hp018 and Hp036) and 1 reference culture (ATCC43504) completely, minimal inhibitory concentration (MIC) is 0.32 μ g/ml.With ampicillin, make positive control, its Cmin (MIC) that 6 strain test bacterium are suppressed is completely 3.5 μ g/ml.
This result of study shows, the energy force rate ampicillin of the inhibition helicobacter pylori activity of Neonectrolide A is strong, explanation for the diseases such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, Neonectrolide A is the compound of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.
The purposes of the Neonectrolide A the present invention relates in preparation treatment Anti-helicobacter pylori drugs belongs to open first, because framework types belongs to brand-new framework types, and it suppresses active strong for helicobacter pylori, possess outstanding substantive distinguishing features, the control for helicobacter pylori infections simultaneously obviously has significant progress.
The specific embodiment
The preparation method of compound N eonectrolide A involved in the present invention is referring to document Jinwei Ren, et al., Neonectrolide A, a New Oxaphenalenone Spiroketal from the Fungus Neonectria sp.Organic Letters, 2012,14(24) 6226 – 6229.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound N eonectrolide A tablet involved in the present invention:
Get 5 and digest compound Neonectrolide A, add 195 grams, dextrin, mix, conventional tabletting is made 1000.
Embodiment 2: the preparation of compound N eonectrolide A capsule involved in the present invention:
Get 5 and digest compound Neonectrolide A, add 195 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
The pharmacological evaluation of experimental example 1:Neonectrolide A
1) strains tested
Helicobacter pylori reference culture ATCC43504 is purchased from U.S.'s strain and preserves center (American Type Culture Collection, ATCC).15 strain Hp clinical strains are picked up from Jiangsu Prov. People's Hospital Gastroenterology dept., clinical laboratory of Jiangsu TCM Hospital and Nanjing Children's Hospital Dndoscope Laboratory and are accepted gastroscopic patient; Patient to peptic ulcer, duodenal bulbar inflammation or gastritis verrucosa in continuous gastroscopy, first through RUT experiment, be defined as Hp positive, get again antral gastric mucosa 1-2 piece, after chopping, be inoculated in the Columbia selectivity agar culture medium containing 8% horse serum, trimethoprim 1.25g/L, Polymyxin B2 500U/L, vancomycin 10mg/L, in 37 ℃, under micro-oxygen environment, (5%O2,10%CO2 and 85%N2) cultivates 72 hours.Collect antibacterial, through smear Gram’s staining, oxidase, catalase and urease are accredited as after the positive, the pure culture of going down to posterity, and obtained strains is as experimental strain.
2) strain culturing
We adopt micro-aerobic bag (purchased from Shanghai Medical Univ) to carry out the strain culturing of HP, and it can produce the needed micro-aerobic environment of Hp by chemical reaction.
3) biological activity determination
Adopt paper disk method to measure the inhibitory action of compound to helicobacter pylori, with agar dilution, measure the minimum inhibitory concentration of test sample.
I. paper disk method experiment
(A) prepare culture medium by the Columbia culture medium preparing after high pressure steam sterilization, be cooled to 50-60 ℃, add 8% horse serum or Sheep Blood, mix in the culture dish that is poured into sterilizing, every ware 7-10ml, culture medium thickness is 1.5mm (sterile working).
(B) switching experimental bacteria (be coated with bacterium) with microscale sampler get diluted 10
8cFU/ml (1OD660=10
8cFU/ml) the bacteria suspension 0.1ml of Hp spreads upon suitable culture dish surface equably.Be inverted in 37 ℃ of drying bakers and take out after 15min, object makes agar surface dry, standby.
(C) pasting the sample scraps of paper gets 6 μ l testing samples (mass concentration 2mg/ml) with microscale sampler and injects on the round filter paper of sterilizing.With aseptic nipper tweezer containing the scraps of paper of sample and contrast blank scraps of paper ，An sterile working respectively the scraps of paper be close to containing bacterio-agar surface, paste at a certain distance a piece of paper sheet.Every kind of bacterium is cooked 3 wares, and acquired results is asked its meansigma methods.
(D) cultivate each plate is placed in to micro-aerobic bag, sealing, opens gas generator, then is placed in 37 ℃ of incubators and cultivates 72h.
(E) survey antibacterial circle diameter and take out after flat board, measure respectively each scraps of paper size of antibacterial circle diameter around.With reference to the result of matched group, can draw the result of testing sample sensitive experiment.In triplicate.
II. agar dilution is measured MIC
(A) first the preparation of medicine flat board becomes dimethyl sulfoxide for compound (DMSO) solution preparation of test the mother solution of 0.5mg/ml, then with sterilized water dilution, is finally made into 10.0,8.0,6.0,4.5,4.0,3.5,3.0,2.5,2.0,1.5,1.0, the concentration series of 0.5 and 0.25 μ g/ml, the concentration of DMSO in medium is less than 1%.The test compounds solution that 1ml is prepared separately adds 1ml in the 9ml Colombia culture medium of 50 ℃ and is incubated in the horse serum of 50 ℃ and fully mixes with being incubated, and casts in culture dish cooling.
(B) switching experimental bacteria (be coated with bacterium) with microscale sampler draw diluted 1 * 10
8the bacteria suspension 0.1ml of CFU/ml Hp spreads upon culture dish surface equably, is inverted in 37 ℃ of drying bakers and takes out after 15min, and object makes agar surface dry, standby.
(C) determine that MIC (contains culture dish to be measured: 85%N2,10%CO at micro-aerobic bag
2and 5%O
2) in, insulation 37oC cultivates 72 hours, observes Hp growing state, with blank group contrast, take and there is no the sample of bacteria growing least concentration completely as minimum inhibitory concentration value.Positive control is ampicillin.
The pharmacological results of Neonectrolide A
Experiment in vitro shows, Neonectrolide A has very strong anti Helicobacter pylori activity, and paper disk method shows that its antibacterial circle diameter is 17mm (ATCC43504).With agar dilution, show that it can suppress the growth of 5 random clinical strains (Hp001, Hp003, Hp004, Hp018 and Hp036) and 1 reference culture (ATCC43504) completely, minimal inhibitory concentration (MIC) is 0.43 μ g/ml.With ampicillin, make positive control, its Cmin (MIC) that 6 strain test bacterium are suppressed is completely 3.6 μ g/ml.
Conclusion: it is strong that Neonectrolide A suppresses the energy force rate ampicillin of helicobacter pylori activity, explanation for the diseases such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, Neonectrolide A is the compound of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.
Claims (1)
- The application of 1.Neonectrolide A in preparing Anti-helicobacter pylori drugs, described compound N eonectrolide A structure is as shown in formula I:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310496280.5A CN103550204A (en) | 2013-10-21 | 2013-10-21 | Application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310496280.5A CN103550204A (en) | 2013-10-21 | 2013-10-21 | Application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103550204A true CN103550204A (en) | 2014-02-05 |
Family
ID=50004683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310496280.5A Pending CN103550204A (en) | 2013-10-21 | 2013-10-21 | Application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103550204A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078970A (en) * | 2015-08-20 | 2015-11-25 | 南京华宽信息咨询中心 | Helicobacter pylori medicine and application thereof |
-
2013
- 2013-10-21 CN CN201310496280.5A patent/CN103550204A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| JINWEI REN,ET AL.: "Neonectrolide A, a New Oxaphenalenone Spiroketal from the Fungus Neonectria sp.", 《ORGANIC LETTERS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078970A (en) * | 2015-08-20 | 2015-11-25 | 南京华宽信息咨询中心 | Helicobacter pylori medicine and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988355A (en) | Application of Aphanamixoid A for preparing helicobacter pylori resistant medicine | |
| CN103550204A (en) | Application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments | |
| CN102861067B (en) | Application of Houttuynoid E in preparing anti-helicobacter pylori (Hp) medicine | |
| CN102861055B (en) | Application of Houttuynoid A in helicobacter pylori resisting medicine | |
| CN102872132B (en) | Application of Houttuynoid D in anti-helicobacter pylori drug | |
| CN102872154B (en) | Application of Houttuynoid B in helicobacter pylori resistant medicament | |
| CN102872131B (en) | Application of Houttuynoid C in preparing anti-helicobacter pylori drug | |
| CN103381165B (en) | Chukrasone A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103446127B (en) | Lycojaponicumin A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103463023B (en) | Application of Lycojaponicumin B in helicobacter pylori resistant medicine | |
| CN103446085B (en) | Incarviatone A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103356600B (en) | Chukrasone B is preparing the application in Anti-helicobacter pylori drugs | |
| CN103356608A (en) | Application of Fluevirosines A in preparing anti-helicobacter pylori medicines | |
| CN103690527B (en) | Aphanamgrandiol A is preparing the application in Anti-helicobacter pylori drugs | |
| CN105535171A (en) | Rose tea | |
| CN102872028B (en) | Application of Gypensapogenin A in medicaments against helicobacter pylori | |
| CN103599097A (en) | Application of Artoxanthochromane in helicobacter pyloridis-resistant drug | |
| CN103479646A (en) | Application of Kadcoccitones A to in preparation of anti-helicobacter pylori medicament | |
| CN102885829A (en) | Application of Gypensapogenin B in helicobacter pylori resistant medicament | |
| CN105078970A (en) | Helicobacter pylori medicine and application thereof | |
| CN103462979A (en) | Application of spirooliganones B in preparation of medicine inhibiting helicobacter pylori | |
| CN105412087A (en) | Application of Parvifloranines A in preparing anti-helicobacter pylori medicine | |
| CN105412052A (en) | Application of Micranthanone A in preparing drugs for anti-helicobacter pylori | |
| CN103356633A (en) | Use of Aspeverin in preparation of drug for resisting helicobacter pylori (Hp) | |
| CN103251639A (en) | Application of Polyflavanostilbene A in preparing anti-helicobacter pylori medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140205 |